Evidence map›Paper›PMID 39890787›Full record

ArticleNPJ vaccines2025

Novel fusion protein REA induces robust prime protection against tuberculosis in mice.

Sintayehu Kebede Gurmessa, Han-Gyu Choi, Yong Woo Back, Zongyou Jiang, Thuy An Pham, Seunga Choi, Hwa-Jung Kim

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Antigen 85B ofVaccines · 2026
    Review
  2. Drug resistance mechanisms inFrontiers in pharmacology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sintayehu Kebede Gurmessa *Department of Microbiology and Medical Science, College of Medicine, Chungnam National University, Daejeon, South Korea.
Han-Gyu Choi *Department of Microbiology and Medical Science, College of Medicine, Chungnam National University, Daejeon, South Korea.
Yong Woo Back *Department of Microbiology and Medical Science, College of Medicine, Chungnam National University, Daejeon, South Korea.
Zongyou JiangDepartment of Microbiology and Medical Science, College of Medicine, Chungnam National University, Daejeon, South Korea.
Thuy An PhamDepartment of Microbiology and Medical Science, College of Medicine, Chungnam National University, Daejeon, South Korea.
Seunga ChoiR&D Center, Myco-Rapha Inc., Daejeon, South Korea.
Hwa-Jung KimDepartment of Microbiology and Medical Science, College of Medicine, Chungnam National University, Daejeon, South Korea. hjukim@cnu.ac.kr.

Funding

Korea Health Industry Development Institute HV23C0057Ministry of SMEs and Startups No. S3321228National Research Foundation of Korea 2020R1A2C1008826
6 · The paper itself

Abstract

While many novel candidates for tuberculosis vaccines are presently undergoing pre-clinical or clinical trials, none of them have been able to eliminate infection entirely. In this study, we engineered a potent chimeric protein vaccine candidate, Rv2299cD2D3-ESAT-6-Ag85B (REA), which induced Th1 and Th17 responses via dendritic cell maturation. REA-activated macrophages operated the killing mechanisms of Mycobacterium tuberculosis (MTB), such as phagosomal maturation and phagolysosome fusion, through the (PI3K)-p38 MAPK-Ca

Identifiers

PMID39890787
PMCPMC11785989

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.